Derm-Biome Pharmaceuticals Inc. has reported findings from a study of its topical drug DB-007-5 in a well-established ...

Researchers have found in a new study that higher plasma omega-3 levels are linked to a reduced risk of atopic dermatitis (AD ...

Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose.

Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...

A global cohort study reveals that dupilumab offers a superior cardiometabolic safety profile for atopic dermatitis patients ...

It can be hard to tell for sure if you have atopic dermatitis, also known as eczema. You’ll want to see a dermatologist or other doctor to find out. At your appointment, your doctor will check ...

The Canine Atopic Dermatitis Treatment Market is projected to grow from USD 1,182.60 million in 2024 to USD 1,620.50 million ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...